title: Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.
abstract: Ovarian cancer has a poor prognosis due to intrinsic or acquired resistance to some cytotoxic drugs, raising the interest in new DNA-binding agents such as mithramycin analogues as potential chemotherapeutic agents in gynecological cancer. Using a genome-wide approach, we have analyzed gene expression in A2780 human ovarian carcinoma cells treated with the novel mithramycin analogue DIG-MSK (demycarosyl-3D-β-D-digitoxosyl-mithramycin SK) that binds to C+G-rich DNA sequences. Nanomolar concentrations of DIG-MSK abrogated the expression of genes involved in a variety of cell processes including transcription regulation and tumor development, which resulted in cell death. Some of those genes have been associated with cell proliferation and poor prognosis in ovarian cancer. Sp1 transcription factor regulated most of the genes that were down-regulated by the drug, as well as the up-regulation of other genes mainly involved in response to cell stress. The effect of DIG-MSK in the control of gene expression by other transcription factors was also explored. Some of them, such as CREB, E2F and EGR1, also recognize C/G-rich regions in gene promoters, which encompass potential DIG-MSK binding sites. DIG-MSK affected several biological processes and molecular functions related to transcription and its cellular regulation in A2780 cells, including transcription factor activity. This new compound might be a promising drug for the treatment of ovarian cancer.
authors.affiliation: Instituto de Biología Molecular de Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona, Spain.
authors.forename: Carolina
authors.initials: C
authors.lastname: Vizcaíno
authors.affiliation: EntreChem, Oviedo, Spain.
authors.forename: Luz-Elena
authors.initials: LE
authors.lastname: Núñez
authors.affiliation: EntreChem, Oviedo, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Morís
authors.affiliation: Instituto de Biología Molecular de Barcelona, Consejo Superior de Investigaciones Cientificas, Barcelona, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Portugal
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D063990:Gene Ontology; D053263:Gene Regulatory Networks / Q000187:drug effects; D015894:Genome, Human / Q000187:drug effects / Q000235:genetics; D023281:Genomics; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D008926:Plicamycin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics; D016329:Sp1 Transcription Factor / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D016329:Sp1 Transcription Factor; D014157:Transcription Factors; C576677:demycarosyl-3D-digitoxosylmithramycin SK; D008926:Plicamycin
references.citation: Transl Res. 2006 Nov;148(5):223-48
references.pmid: 17145569
references.citation: BMC Bioinformatics. 2013 Apr 15;14:128
references.pmid: 23586463
references.citation: Nucleic Acids Res. 2007;35(7):2215-26
references.pmid: 17369273
references.citation: J Natl Cancer Inst. 2011 Jun 22;103(12):962-78
references.pmid: 21653923
references.citation: Nucleic Acids Res. 2006 Mar 29;34(6):1721-34
references.pmid: 16571899
references.citation: Oncogene. 1995 Jun 15;10(12):2323-30
references.pmid: 7784080
references.citation: Nucleic Acids Res. 2001 May 1;29(9):e45
references.pmid: 11328886
references.citation: Biochem Pharmacol. 2012 Nov 1;84(9):1133-42
references.pmid: 22981341
references.citation: Lancet. 2009 Oct 17;374(9698):1371-82
references.pmid: 19793610
references.citation: Appl Microbiol Biotechnol. 2006 Nov;73(1):1-14
references.pmid: 17013601
references.citation: Cancer Res. 2007 May 15;67(10):4878-85
references.pmid: 17510417
references.citation: BMC Syst Biol. 2011 Sep 19;5:144
references.pmid: 21923952
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2988-97
references.pmid: 18790779
references.citation: PLoS One. 2012;7(4):e35130
references.pmid: 22545098
references.citation: Adv Cancer Res. 2010;107:163-224
references.pmid: 20399964
references.citation: J Med Chem. 2012 Jun 28;55(12):5813-25
references.pmid: 22578073
references.citation: Chem Biol Interact. 2014 Aug 5;219:123-32
references.pmid: 24907531
references.citation: Biochim Biophys Acta. 2013 Jan;1835(1):76-85
references.pmid: 23147197
references.citation: Nature. 2012 Mar 28;483(7391):603-7
references.pmid: 22460905
references.citation: J Ovarian Res. 2011 Sep 09;4:16
references.pmid: 21906307
references.citation: Eur J Biochem. 2003 Feb;270(4):764-70
references.pmid: 12581216
references.citation: Metab Eng. 2013 Nov;20:187-97
references.pmid: 24148183
references.citation: Eur J Cancer. 2005 Nov;41(16):2438-48
references.pmid: 16209919
references.citation: Nature. 2011 Jun 29;474(7353):609-15
references.pmid: 21720365
references.citation: Biochemistry. 2010 Dec 14;49(49):10543-52
references.pmid: 21067184
references.citation: J Biol Chem. 2006 Jul 28;281(30):21433-21444
references.pmid: 16714763
references.citation: Mol Pharmacol. 2005 Nov;68(5):1496-503
references.pmid: 15961672
references.citation: Int J Cancer. 2008 Mar 15;122(6):1430-4
references.pmid: 18027851
references.citation: Trends Mol Med. 2011 Oct;17(10):537-8
references.pmid: 21775208
references.citation: Int J Cancer. 2010 Aug 15;127(4):977-88
references.pmid: 20013802
references.citation: Gynecol Oncol. 2010 Aug 1;118(2):182-8
references.pmid: 20452660
references.citation: Nucleic Acids Res. 2010 Jan;38(Database issue):D204-10
references.pmid: 20015972
references.citation: J Exp Clin Cancer Res. 2010 Jun 03;29:62
references.pmid: 20525245
references.citation: Bioinformatics. 2005 Mar;21(6):803-10
references.pmid: 15374858
references.citation: Chembiochem. 2008 Sep 22;9(14):2295-304
references.pmid: 18756551
references.citation: J Am Chem Soc. 2003 May 14;125(19):5745-53
references.pmid: 12733914
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: PLoS One. 2012;7(8):e41664
references.pmid: 22899999
references.citation: Clin Cancer Res. 2008 May 15;14(10):3030-5
references.pmid: 18483368
references.citation: Br J Cancer. 2013 Feb 5;108(2):250-8
references.pmid: 23385789
references.citation: Biotechniques. 2003 Feb;34(2):374-8
references.pmid: 12613259
references.citation: PLoS Med. 2009 Feb 3;6(2):e24
references.pmid: 19192944
references.citation: Cancer Lett. 2011 Oct 1;309(1):11-8
references.pmid: 21676537
references.citation: Cancer. 2004 May 15;100(10):2139-47
references.pmid: 15139056
references.citation: Yonago Acta Med. 2013 Jun;56(2):43-50
references.pmid: 24031151
references.citation: Oncologist. 2001;6(2):162-76
references.pmid: 11306728
references.citation: Cancer Res. 2010 Jun 1;70(11):4613-23
references.pmid: 20460525